Salubris Wins Clinical Trial Approval for siRNA Drug SAL0195 Targeting Elevated Lipoprotein(a)
Salubris announced that it has received the Clinical Trial Approval Notice issued by the National Medical Products Administration, approving the company's independently developed innovative siRNA drug SAL0195 injection (project code: SAL0195) to conduct clinical trials for the treatment of elevated lipoprotein(a). The notice was obtained on August 7, 2026.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Biotechnology, with intensity 30/100 and 60% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.